Curis

Curis R&D per Employee

The R&D Spending per Employee of Curis (CRIS) as of Nov 21, 2026 is 554,000.00 USD. In the previous year, R&D Spending per Employee was 756,117.65 USD — a change of -26.73% (lower).

R&D per Employee

554,000.00USD

YoY

-26.73%

Last updated:

R&D Spending per Employee of Curis is 2025 554,000.00 USD. R&D Spending per Employee of Curis was 2024 756,117.65 USD. It decreases by -26.73% lower compared to the previous year.

The Curis R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
478,686.27 USD
Jan 1, 2019
437,294.12 USD
Jan 1, 2020
452,313.73 USD
Jan 1, 2021
684,000.00 USD
Jan 1, 2022
848,568.63 USD
Jan 1, 2023
774,431.37 USD
Jan 1, 2024
756,117.65 USD
Jan 1, 2025
554,000.00 USD
The Curis R&D per Employee history
YEARR&D per EmployeeYoY
554,000.00USD-26.73%
756,117.65USD-2.36%
774,431.37USD-8.74%
848,568.63USD+24.06%
684,000.00USD+51.22%
452,313.73USD+3.43%
437,294.12USD-8.65%
478,686.27USD-26.78%
653,803.92USD+5.55%
619,411.76USD+18.32%
523,517.06USD+95.47%
267,831.33USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

R&D Spending per Employee of Curis is 554,000.00 USD in 2025.

R&D Spending per Employee of Curis changed from 756,117.65 USD to 554,000.00 USD, representing a -26.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Curis since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Curis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Curis

All Key Metrics — Curis